Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
:MRK
MRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$81.04 - $134.63
Previous CloseN/A
Volume3.30M
Average Volume (3M)15.86M
Market Cap
$210.69B
Enterprise Value$312.11B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)12.4
Beta0.27
Next Earnings
Apr 24, 2025EPS Estimate
2.13Next Dividend Ex-Date
Mar 17, 2025Dividend Yield3.75%
Share Statistics
EPS (TTM)6.73
Shares Outstanding2,529,635,700
10 Day Avg. Volume20,417,013
30 Day Avg. Volume15,863,175
Standard Deviation0.06
R-Squared0.10
Alpha0.00234
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.34
Price to Cash Flow (P/CF)5.70
P/FCF Ratio6.20
Enterprise Value/Market Cap1.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.10
Enterprise Value/Ebitda16.28
Forecast
1Y Price Target
$114.12Price Target Upside33.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationsThe analyst maintains a Buy recommendation, suggesting the upside potential outweighs the downside risk at the current valuation levels.
Pipeline And DiversificationMerck is addressing short-term concerns by diversifying their pipeline, showing management confidence.
Valuation And Growth PotentialDespite current setbacks, the stock is deemed undervalued with a strong late-stage pipeline and an above-average growth profile.
Bears Say
Competitive PressureThe stock is expected to remain under pressure due to upcoming data from competitors Avanzar and Summit.
Gardasil ChallengesGardasil issues have caused previous guidance to be withdrawn, and sales in China are halted until inventories normalize.
Revenue ExpectationsThe 2025 revenue guidance missed both consensus and analyst estimates.
---
Ownership Overview
0.05% Insiders
21.59% Mutual Funds
15.64% Other Institutional Investors
41.35% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $81.04 and its highest was $134.63 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $210.69B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Apr 24, 2025 which is in 63 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Feb 04, 2025. The company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.609 by $0.111.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 3.75%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.13.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,529,635,700 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $1.72 in its last earnings report, beating expectations of $1.609. Following the earnings report the stock price went down -9.069%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
---
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$114.12 (33.32% Upside)
$114.12 (33.32% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $855.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.18%
12-Months-Change
Fundamentals
Return on Equity
27.30%
Trailing 12-Months
Asset Growth
10.12%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
MRK Company Deck
---
MRK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with strong performance in key areas like oncology and new product launches, but challenges persist with GARDASIL in China and impacts from Medicare Part D redesign. Although the company remains confident in its long-term growth potential, short-term headwinds are acknowledged.Read More>---
MRK Sales Breakdown
89.13% Pharmaceutical
9.36% Animal Health
1.51% Other
---
MRK Stock 12 Month Forecast
Average Price Target
$114.12
▲(33.32% Upside)
Technical Analysis
Best Analysts Covering MRK
1 Year
1 Year Success Rate
16/23 ratings generated profit
1 Year Average Return
+6.51%
reiterated a buy rating 16 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +6.51% per trade.
---